Serum Asprosin level in acromegaly patient: does Diabetes has an impact on it?

Abstract The anterior pituitary gland's overproduction of growth hormone is the cause of acromegaly. Chronic hyperglycemia brought on by abnormalities in insulin secretion or action is a hallmark of diabetes mellitus type 2, a group of metabolic disorders.  Asprosin, a newly discovered adipocyte produced from profibrillin-1, promotes hepatic glucose release during fasting. Diabetic and pre-diabetic patients show increased asprosin levels, whereas acromegaly patients exhibit significantly lower serum asprosin levels. Estimating the levels of acromegaly and its relationship to the other parameters is the aim of the current investigation. The National Diabetic Center at Mustansyrriah University recruited sixty patients (31 with diabetic acromegaly and 29 with acromegaly without diabetes), and thirty control groups (diabetic without acromegaly) were examined there for the biochemical study's criteria. Biochemical indicators such as asprosin, GH, IGF-1, responsiveness to octreotide, and LDL and triglyceride levels were altered in acromegalic patients. According to the current study, asprosin levels are higher in patients with acromegaly than in those without the disease. This is true whether or not a patient has acromegaly. Patients with acromegaly had higher levels of growth hormone and IGF-1, and non-diabetic acromegaly responds better to octreotide than diabetic acromegaly. Diabetes non-acromegaly was reported to have lower LDL and triglyceride levels than diabetic patient with acromegaly.